Director resigns citing governance concerns; Bioxytran hires independent expert for controls review

BIOXYTRAN, INC

Anders Utter resigns from Bioxytran's Board and Audit Committee chair, effective Dec 7, 2025, citing need for enhanced oversight and controls.
Utter's recommendations included strengthening segregation of duties, improving financial approval documentation, and legal review of a recent stock issuance.
Company engages an independent third-party financial expert to review oversight, internal controls, and approval processes.
No disagreement related to financial statements, accounting practices, or SEC disclosures, per filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.